Secure the Next Commitment: Evidence based FTO decisions with Dr. Christian Heubeck

I. Initial Situation and Central IP Question

rnhale is developing a platform for the local delivery of RNA therapeutics to the lungs. RNA, lipid-based carriers, dry powder, manufacturing processes and the inhalation device must work together. The published case describes the transition to preclinical development, process scale-up and clinical preparation. Alongside its own drug programmes, collaborations and licences are intended to enable further applications. Decisions made today therefore affect both the first product and the reusability of the platform.

The starting point is the Practical Question: Continuous Freedom to Operate. Keeping an Inhaled RNA Platform Clear to Market with Benjamin Winkeljann.

The proposed solution focuses on the next development step that will be difficult to reverse. Before committing to equipment procurement, a defined process or an exclusive collaboration, management should know which course of action is supportable on the available evidence. The public case does not provide specific claim analyses, contractual documents or development data. The following decision rules are therefore proposed for professional review; the application example is explicitly hypothetical.

The guiding question is: What evidence and access rights does rnhale need before making its next capital commitment, and which alternative must remain genuinely available until then?

II. Solution Position: Secure the Next Commitment

“Each irreversible development commitment should be backed by claim-specific evidence, executable access rights and a funded fallback.”

The commercial purpose of this approach is to address avoidable dependencies before switching costs increase. A patent finding is prioritised when it affects an upcoming investment, a platform component used across several programmes or a partner contribution that would be difficult to replace. As a result, a technically attractive route may require additional evidence before the company continues to fund it.

The proposed core model is called the Commitment Readiness Test. It combines four dimensions: Evidence, Reversibility, Access and Reuse. The test examines the robustness of the claim assessment, the cost of changing course later, the practical availability of the required rights and their availability for follow-on programmes. The outcome is a defined management decision with conditions, a budget and a review date.

This perspective has been developed editorially from Heubeck’s documented fields of practice: FTO, patent proceedings, challenges to third-party rights, licence agreements and portfolio strategy. His biochemical research on ribonucleases provides a scientific point of reference for RNA-related matters. The model itself is submitted to him for review.

Further Reading: This contribution connects Heubeck’s life sciences perspective with financing, portfolio design and continuous competitive monitoring. It therefore deepens the commercial rationale for evidence-based investment decisions in the present case.

👉 IP Protection in the Life Sciences: Turning Innovation into Market Success

III. Application to the Value Creation Architecture

For the RNA payload and lipid carrier, value arises from the intended biological effect and effective delivery. Specific sequence features, modifications, lipid structures and compositions must be documented. For each prioritised claim, the team records which features are technically present, which are absent and which remain unclear. A change of material requires a new assessment of the affected combination; any supplier statement is reviewed for its precise scope.

The dry-powder formulation combines stability with inhaled administration. R&D should therefore compare variants against predefined performance criteria, such as RNA integrity, aerosol behaviour and biological activity. In parallel, patent counsel assesses whether the respective variant actually avoids a relevant claim. The evidence from these two assessments determines whether an alternative can be budgeted as a fallback route.

Reproducibility and transferability are central to manufacturing processes and analytics. Before equipment is selected, the process steps, critical parameters and external contributions must be recorded. To enable a later change of manufacturer, rnhale needs usable documentation, contractual rights of use and a technically plausible transfer route. This assessment is brought forward as soon as an investment increases dependence on a particular supplier.

The device, dosage and indication define the specific application. Changing the inhaler may create new technical interfaces and IP questions. Market priorities are therefore set for each programme on the basis of patient benefit, partner demand and the development pathway. Countries of manufacture, clinical trials and sale are recorded separately; the sales market alone does not fully describe the relevant activities.

The proposed prioritisation begins with the first candidate and the components used across the platform. Additional variants are initially grouped according to technical proximity and commercial significance. Only differences that are relevant to the decision trigger a detailed individual assessment.

Further Reading: This Research Nugget explains how companies identify change, mobilise resources and adapt capabilities. For rnhale, this supports the connection between patent monitoring, funded technical alternatives and an adaptable partner structure.

👉 David Teece’s Dynamic Capabilities

IV. Operational Decision Model

The Commitment Readiness Test is applied before candidate selection, formulation lock-in, process commitment, a clinical development step or a material partner agreement. In each case, the scope of the assessment follows the specific action being planned.

1 . Evidence asks: Which claim could cover which activity involving which product version? Patent counsel documents the claim wording, legal status, territory, technical feature mapping and any remaining questions of interpretation. Pending applications are tracked separately as potential future constraints. A relevant unknown remains visible as an open condition.

2 . Reversibility asks: Which change will become more expensive or time-critical after this step? Development and manufacturing quantify the experimental work required, sunk costs, transfer time and any additional regulatory work. This establishes the last reasonable date for selecting an alternative.

3 . Access asks: Can rnhale and the intended participants perform the next activity? The assessment covers development, third-party manufacturing, the transfer of required know-how, sublicensing, territories and the continuing validity of the rights. A potential outcome of negotiations is treated as secured access only once a binding agreement has been reached.

4 . Reuse asks: Which follow-on programmes remain feasible with these rights and data? Business Development examines further payloads, indications and partners in particular. Any restriction must be expressly reflected in commercial planning.

Approval is granted for a defined scope. Conditional approval permits limited work subject to a cost ceiling, deadline and stop criterion. Deferral applies to the specific commitment for which the necessary conditions are not yet met. Material gaps are decided individually; an average score across the four dimensions could conceal them.

Hypothetical application: A new lipid carrier improves the formulation, but its relationship to relevant claims remains unclear before process scale-up. The initial proposal is a limited comparative experiment using the existing variant together with a more detailed claim assessment. Commitment to the specific equipment is deferred until the agreed decision date. If a relevant right and commercially viable access terms are confirmed, the licensing route may be preferred. If the alternative fails to meet the minimum performance requirements, it loses its status as a fallback route. If neither access nor a viable alternative is available, the commitment is deferred and programme planning is adjusted.

Further Reading: This lecture connects FTO findings with specific development decisions and the comparison of alternative routes. The Commitment Readiness Test translates this relationship into verifiable conditions for the next capital commitment.

👉 Continuous Freedom to Operate: Product Decisions, Platform Rights and Partner Readiness

V. Implementation in IP Management and the Portfolio

A six-week work cycle is proposed for implementation. During the first two weeks, Development and Management define the next relevant commitment, the product versions and the countries concerned. Patent counsel, Manufacturing and Business Development then jointly prepare the prioritised evidence and options. At the end of the cycle, Management decides on the next step. Extensive searches or negotiations may continue beyond this period; each open item is assigned its own deadline.

Each critical finding is captured in a short Decision Record: the affected activity, status of the evidence, decision, responsible person, budget, conditions and review trigger. Development is responsible for technical features and performance evidence, patent counsel for the legal assessment, Manufacturing for transfer requirements and Business Development for commercial scope. Management owns the investment decision, including the documented residual risk.

The same time horizon is used for a licence, a technical alternative and, where appropriate, a validity challenge. Payments, experimental work, delay and effects on follow-on programmes are compared. Ranges and sensitivities show which cost or timing factor would change the preferred route. A challenge to an IP right receives its own funding and timetable; its uncertain outcome does not constitute advance clearance.

Proprietary inventions arising from formulation and process work are captured before disclosure. Patent protection is determined by the demonstrable technical contribution and commercial scope. Reproduction know-how is subject to documented confidentiality and access rules. Data maturity, publications and financing are jointly scheduled for patent filings. Building proprietary exclusionary rights and securing access to third-party technologies remain two separate questions requiring separate answers.

Further Reading: Heubeck’s contribution addresses the relationship between invention maturity, disclosure planning, budget and filing date. It supports the alignment of proprietary IP decisions with rnhale’s development steps and financing constraints.

👉 Timing of patent applications in the life sciences industry

VI. Strategic Development and Partner Rights

A new claim wording, patent grant, relevant procedural decision or technical change is assessed to determine whether it affects an existing Decision Record. The same applies to a new manufacturer, an additional indication or amended licence terms. The responsible person first updates the affected decision; components used across the platform trigger a review of every dependent programme. The relevant time horizon is the period until the next commitment or applicable procedural deadline.

For collaborations, a Reuse Schedule is proposed as an annex to the agreement. It describes the background knowledge contributed, the results that may arise and who may use them for which programmes. For improvements, ownership, rights of use and access to practical implementation are addressed separately. Particularly relevant issues include manufacturing rights, use of data, sublicensing, availability after termination and transfer support.

A practical stress test asks: Could rnhale use an improved powder formulation with another manufacturer for a further payload after the collaboration ends? If parameters, analytical data or required rights are missing, this gap is negotiated before the collaboration begins. Where a restriction is commercially acceptable, Management must expressly accept its consequences for the valuation of the platform.

A change in the regulatory development plan may also alter the value of an alternative. New requirements are therefore translated into cost and time implications together with Regulatory Affairs. The next FTO decision uses these updated assumptions.

Further Reading: Heubeck’s contribution connects market monitoring, competitive intelligence and FTO analysis in the life sciences. For the proposed solution, it provides the professional basis for event-driven reassessments of development decisions already made.

👉 Market monitoring and FtO analysis in the life sciences industry

VII. Practical Decision Overview

The overview condenses the test for typical commitments in the case. Each row is completed for a specific variant, activity and jurisdiction. Patents, contracts and protected manufacturing know-how perform different functions that together determine feasibility.

For manufacturing know-how, the protection architecture comprises controlled documentation, role-based access and traceable transfer. Contractual rights of use must include access to the information required for this purpose. A documented transfer exercise can test whether the intended reusability exists in practice. A successful technical transfer remains subject to the necessary IP assessment.

Further Reading: This contribution explains how critical knowledge is documented, protected and kept usable during organisational change. It deepens the connection between trade secret protection, contractual access and a change of manufacturer at rnhale.

👉 Know-how Management

VIII. Governance and Continuous Adaptation

Management embeds the test in existing development decisions. A monthly review of critical changes is recommended as a starting point, supplemented by assessments before relevant commitments. For new findings, patent counsel determines urgency according to legal significance and proximity to the decision. Time-critical matters are escalated directly to the responsible executive.

Three metrics make implementation visible: the proportion of upcoming commitments with a current Decision Record, overdue material conditions and critical dependencies without a funded alternative course of action. These values support resource allocation. They do not provide a general statement of legal certainty.

A dossier with tiered access is prepared for partners and investors. It contains the product scope, status of the assessment, chains of access rights and outstanding actions. The disclosure of legal analyses is agreed with counsel in advance. Search limitations and remaining uncertainties are presented as transparently as the issues already resolved. This enables third parties to understand the next development decision and better assess the work required before entering into a partnership.

Further Reading: This contribution positions IP within the business model, cross-functional organisation and recurring strategic review. It supports the integration of the Commitment Readiness Test into rnhale’s regular management processes.

👉 The 360° IP Strategy: Securing Long-Term Innovation Success

Outcome

Secure the Next Commitment combines specific claim evidence with switching costs, executable access rights and platform reuse. The proposed starting point is a decision on the next material development step, with a named owner, limited budget and verifiable conditions. The expected outcomes are better-founded capital commitments, earlier action on critical dependencies and a traceable basis for partner discussions. Its value is demonstrated by whether rnhale still has actionable options when new information emerges.

“Which evidence, access rights and funded alternatives must rnhale secure before its next development commitment?”

Expert Profile: Dr Christian Heubeck

Dr Christian Heubeck holds a Diplom in Chemistry and is a partner at Weickmann & Weickmann in Munich. He has been a German and European Patent Attorney since 2008, a partner since 2011 and a UPC Representative since 2023. He studied chemistry in Würzburg and Galway and completed his doctorate in 2003 on the composition of eukaryotic ribonuclease P in plants and plastids. His firm profile lists biochemistry, immunology, pharmaceuticals and medical technology, as well as FTO analyses, licence agreements, patent portfolios and the defence and challenge of IP rights.

On the IPBA platform, Heubeck makes this professional connection accessible through an integrated knowledge base. His dIPlex topic area IP Protection in the Life Sciences connects the commercial logic of protection with international strategies, filing dates and continuous FTO monitoring. Particularly relevant to the case is his page on Market Monitoring and FTO, linked above. It also offers his white paper “Freedom to Operate in the Life Sciences: Securing Innovation Pathways”.

The contribution on filing dates supports the alignment of research progress and disclosure. Global IP protection strategies in the life sciences industry adds the international perspective. The IPBA contribution linked above, based on his participation in IP Management Voice, also explains the commercial function of life-sciences IP. For a dialogue with rnhale, the particular value of these contributions lies in their connection between scientific development, IP decisions and commercial implementation.